

February 6, 2021

The Manager- Listing

**BSE Limited**

Corporate Relationship Dept., 5<sup>th</sup> Floor, New Trading Ring  
Rotunda Building, P J Towers, Dalal Street, Fort,  
Mumbai - 400001

The Manager- Listing

**National Stock Exchange of India Limited**

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra –Kurla Complex, Bandra (E),  
Mumbai - 400051

Dear Sir(s),

**Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg**

This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (**Subsequent New Drug Approval**) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg.

Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m<sup>2</sup>).

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses.

We request you to kindly take the same on record.

For **AstraZeneca Pharma India Limited**

**Pratap Rudra**

**Company Secretary & Legal Counsel**